<DOC>
	<DOC>NCT01285492</DOC>
	<brief_summary>This is a 52-week treatment, multi-center, randomized, open label, parallel group study to assess the long term safety and tolerability of once-daily QVA149 (indacaterol and NVA237 ([glycopyrronium bromide]) using tiotropium as an active control in Japanese patients with moderate to severe chronic obstructive pulmonary disease (COPD).</brief_summary>
	<brief_title>Long Term Safety and Tolerability of QVA149 Versus Tiotropium in Japanese Patients With Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<mesh_term>Glycopyrrolate</mesh_term>
	<criteria>Patients with moderate to severe stable COPD (Stage II or Stage III) according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines 2008. Current or exsmokers who have a smoking history of at least 10 pack years. (Ten pack years are defined as 20 cigarettes a day for 10 years, or 10 cigarettes a day for 20 years etc.) Patients with postbronchodilator forced expiratory volume in one second (FEV1) â‰¥30% and &lt; 80% of the predicted normal, and postbronchodilator FEV1/forced vital capacity (FVC) &lt; 0.7 at Visit 2. Pregnant women or nursing mothers or women of childbearing potential not using an acceptable method of contraception Patients requiring long term oxygen therapy Patients who have had a lower respiratory tract infection within 4 weeks prior to Visit 1 Patients with concomitant pulmonary disease Patients with a history of asthma Any patient with history of malignancy of any organ system (including lung cancer), treated or untreated, within the past 5 years Patients with a history of certain cardiovascular comorbid conditions Patients with a known history and diagnosis of alpha1 antitrypsin deficiency Patients in the active phase of a supervised pulmonary rehabilitation program Patients contraindicated for treatment with, or having a history of reactions/ hypersensitivity to anticholinergic agents, long and short acting beta2 agonists, sympathomimetic amines Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>COPD</keyword>
	<keyword>QVA149</keyword>
	<keyword>NVA237</keyword>
	<keyword>indacaterol</keyword>
	<keyword>combination bronchodilator</keyword>
</DOC>